Business News

The FDA approves Gamifant ® (EMAPALUMAB-LZSG) as the first treatment for adults and children with macrophage activation syndrome in Still’s disease


The FDA approves Gamifant ® (EMAPALUMAB-LZSG) as the first treatment for adults and children with macrophage activation syndrome in Still’s disease

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Check Also
Close
Back to top button